Johnson and Johnson

04:33 EDT 26th August 2019 | BioPortfolio

Johnson & Johnson is a leading pharmaceutical and healthcare company, with annual sales in 2009 of $22,520 million, ranking it the 8th largest pharmaceutical company in the world (based on sales).

Medical and Diagnostic devices is a large interest of J&J, with products across all fields of medicine from Orthopedics prosthesis to diabetic insulin blood tests. In 2010, annual sales were $23.6 billion, making in the number 1 medical device company (based on annual sales)

Medications produced by J&J target the following main areas; cardiovascular and metabolic disease, immunology, infectious diseases, neuroscience and oncology; and are the result of an annual investment of $4.6bn in R&D. Some of the main medications include Reminyl, Invega, Axert and Topamax.

In addition to these areas, J&J also invests in products that are household names, such as baby care, dental hygiene, visual hygiene and health dietary components.

Source;, and Fierce BioTech

Add the Johnson & Johnson News Channel to your RSS reader;

Follow the Johnson & Johnson Twitter feed;

Quick Search

review and buy Johnson and Johnson market research data and corporate reports here